



The reported frequency of Mycobacterium tuberculosis infec-
tion in solid organ transplant recipients varies from 0.2% to
15% (mean, 3.7%), which is 6 to 62 times higher than the fre-
quency in the general population (0.01% to 0.045%) [1]. The
incidence of tuberculosis (Tb) in the general population is the
principle predictor of the increased frequency noted in the
transplant recipients. In North America, solid organ recipients
experience posttransplantation Tb at a frequency of 0.5% to
1%, whereas recipients from countries in which Tb is more
prevalent, such as India and Pakistan, report a frequency of
approximately 9% [1]. In comparison with solid organ trans-
plant recipients, allogeneic stem cell transplant (alloSCT)
recipients have rarely been reported to develop mycobacterial
infections. In Western countries, the frequency of Tb in these
patients is lower, varying between 0.13% and 2.2%, probably
because of the transfer of puriﬁed protein derivative (PPD)-
speciﬁc T-cell immunity of the donor and the shorter period of
immunosuppression compared with that of solid organ trans-
plant recipients [2-8]. However, lower prevalence of Tb infec-
tion after alloSCT has not been conﬁrmed in developing coun-
tries, such as Turkey, where Tb infection is more prevalent [9].
The aim of this retrospective survey was to determine
the frequency of Tb infection in adult alloSCT recipients
in Turkey and to evaluate the influence and toxicity of iso-
niazid (INH) prophylaxis.
PATIENTS AND METHODS
This retrospective survey was carried out at 4 bone mar-
row transplantation (BMT) units in Turkey. A total of
351 adult alloSCT recipients were studied: 185 patients from
Ankara Ibni-Sina Hospital (A), 74 patients from Istanbul
School of Medicine (I), 50 patients from Cerrahpasa School of
Medicine (C), and 42 patients from Marmara School of Medi-
cine (M) (Table 1). We reviewed the hospital and outpatient
follow-up records of these 351 patients who underwent unma-
nipulated alloSCT between January 1988 and August 1998.
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ABSTRACT
In general, tuberculosis (Tb) is rarely seen in allogeneic stem cell transplant (alloSCT) recipients, but this observa-
tion has been challenged in developing countries such as Turkey, where Tb infection is more prevalent than in
Europe and the US. In this retrospective study, we report on the incidence of Tb infections in 351 alloSCT recipi-
ents at 4 bone marrow transplantation units in Turkey over the last 10 years. The frequency of Tb in alloSCT recip-
ients after allografting (5 of 351) was far greater than that in the general population (35.4 per 100,000). Of the
351 patients who underwent alloSCT, 77 who received isoniazid (INH) chemoprophylaxis for 6 months did not
develop posttransplantation Tb. However, 5 of the remaining 274 patients who received no chemoprophylaxis
developed Tb a median of 12 months (range, 10-47 months) after allografting. Antituberculosis therapy resulted in
complete recovery in all cases. In 2 additional patients who were found to have active pulmonary Tb at the time of
transplantation, alloSCT was delayed until the infections were treated. Infections of mycobacteria other than
Mycobacterium tuberculosis were not observed. The number of patients who received and tolerated INH may not be
sufficient for firm conclusions, but the data suggest that, in countries where Tb is prevalent, pre- and posttransplan-
tation follow-up for Tb and the use of INH prophylaxis should be considered.
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All transplants were from HLA-matched relatives: 347
were HLA-identical siblings; 2 were HLA-identical nonsib-
ling family members; and 2 were siblings with a single HLA
antigen mismatch. The median age was 30 years (range, 15-
54 years), 132 (37.6%) of the patients were female, and 219
(62.4%) were male (Table 1). The primary diagnosis was
acute myeloblastic leukemia (AML) in 135 patients (38.5%),
acute lymphoblastic leukemia in 48 patients (13.7%), and
chronic myeloid leukemia (CML) in 114 patients (32.5%);
the remaining 54 patients (15.4%) had severe aplastic ane-
mia, myelodysplastic syndrome (MDS), or multiple myeloma
(Table 1). All had been vaccinated in infancy with bacillus
Calmette-Guérin (BCG).
All patients received the same graft-versus-host dis-
ease (GVHD) prophylaxis of cyclosporin A and short-
term methotrexate. Diagnosis and grading of acute
GVHD were based on clinical evaluation and histologic
confirmation [10], and the patients who had grade II to IV
acute GVHD were treated. Chronic GVHD and veno-
occlusive disease (VOD) were diagnosed and graded
according to Seattle criteria [11,12].
The 4 transplant units had different pretransplantation
evaluation schedules and posttransplantation prophylaxis
policies with respect to Tb. All centers screened patients
with chest radiogram before transplantation, and patients
who had inﬁltrates or suspicious lesions were evaluated with
computed tomography and, if required, bronchoscopy.
Two centers (A and C, accounting for 235 patients) did not
give patients the tuberculin skin test before transplantation,
nor did they give INH prophylaxis after allografting. In the
other 2 BMT units (I and M, accounting for 116 patients),
all the recipients were screened by intradermal injection of
5 units of tuberculin PPD (Mantoux test) before alloSCT.
All PPD readings were made by pen technique at 72 hours
according to Howard and Solomon [13]. The Mantoux test
was not repeated in patients with negative results. In BMT
unit I, all 74 patients, regardless of Mantoux test results,
received INH prophylaxis at a dose of 300 mg/day po start-
ing 5 days before alloSCT and continuing for 6 months. In
BMT unit M, only the patients who had a positive tuberculin
reaction (an induration greater than 15 mm at 72 hours) (3 of
47 patients) received the INH prophylaxis.
All samples, including sputum, bronchoalveolar lavage
ﬂuid, and urine, were evaluated for acid-fast bacilli by direct
examination of the sample with Ziehl-Neelsen stain, and all
were cultured using either Lowenstein-Jensen medium or
BACTEC-460 liquid medium (BD Biosciences, Cedex, France).
Serum aminotransferase (alanine and aspartate transam-
inase [ALT and AST]) levels were closely followed for signs
of hepatotoxicity in patients receiving INH prophylaxis.
During the ﬁrst month, serum aminotransferase levels were
checked every other day, and then weekly for 6 months.
Aminotransferase elevations of 2- to 3-fold without associ-
ated findings of VOD, acute GVHD [11,12], or cyclo-
sporin A toxicity prompted a cessation of INH. If amino-
transferase elevations continued despite cessation of INH,
the other prophylactic drugs (such as f luconazole,
trimethoprim-sulfamethoxazole, and acyclovir) were con-
sidered to be the cause of hepatotoxicity, and their gradual
elimination was pursued. Also, in the patients who had pro-
gressive hepatic deterioration due to either VOD or acute
GVHD, INH prophylaxis was halted.
RESULTS
Of the 116 recipients in 2 centers (I and M) who were
tested before alloSCT, the PPD reaction size was less than
10 mm in 80 (69%), 11 to 15 mm in 29 (25%), and >15 mm
in 7 (6%) (Table 2). None of the 7 patients (3 from center M
and 4 from center I) who had a positive PPD with a normal
chest radiogram before transplantation developed posttrans-
plantation Tb (Table 2).
Posttransplantation Tb infection occurred in 5 of
351 patients. These 5 patients (3 from center M and 2 from
center A) had normal chest radiograms before transplanta-
tion. In 2 patients at center A, PPD was not tested before
transplantation; interestingly, PPD was <10 mm in the other
3 patients (center M) (Table 3).
Tb diagnosis was “certain” in 4 cases: M tuberculosis was
cultured from sputum or from bronchoalveolar lavage ﬂuid
in 3 patients and from urine in 1 patient. Tuberculosis was
considered “probable” in 1 patient who had a clinical picture
highly suggestive of Tb: right upper lobe inﬁltration, night
sweats, weight loss, and sustained fever. His pneumonia did
not resolve with azithromycin but did resolve with antitu-
berculous treatment. None of the patients with Tb had
copathogens. Infections due to mycobacteria other than
M tuberculosis were not encountered. No patient had a
known personal or family history of Tb, and none had a his-
Table 1. Demographic and Clinical Features of the Patients*
Bone marrow transplantation unit
Ankara Ibni-Sina Hospital 185 
Istanbul School of Medicine 74 
Cerrahpasa School of Medicine 50 
Marmara School of Medicine 42 
Female sex 132 (37.6) 
Age, y (median [range]) 30 (15-54)
Graft source
Peripheral blood stem cells 146 (41.6)
Bone marrow 205 (58.4)
GVHD prophylaxis Cyclosporin A and
short-term methotrexate 
Primary diagnosis
Acute myeloblastic leukemia 135 (38.5)
Acute lymphoblastic leukemia 48 (13.7)




Bu/Cy ± VP16§ 244 (69.5)
Other 18 (5.1)
Acute GVHD 172 (49)
Grade II-IV 119 (33.9)
Veno-occlusive disease 13 (3.7)
*Data are n or n (%), unless otherwise specified. GVHD indicates
graft-versus-host disease.
†Aplastic anemia, multiple myeloma, and myelodysplastic syndrome.
‡Cyclophosphamide (120 mg/kg) and total body irradiation (12 Gy).
§Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) with or
without etoposide (30 mg/kg).
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tory of close contact with someone who had active Tb. Clin-
ical characteristics of these patients, including results of the
tuberculin reaction before transplantation, time of Tb diag-
nosis, and GVHD stages, are summarized in Table 3.
Two patients had pulmonary Tb at the time of alloSCT.
In one, whose primary diagnosis was CML, alloSCT was
carried out after a complete 6-month course of antitubercu-
lous treatment. The other, who had AML transformed from
MDS, received antituberculous drugs for 4 months followed
by alloSCT with antituberculous treatment. The disease has
not recurred in either of the 2 patients.
In only 1 alloSCT recipient, who had Tb 15 months
after transplantation, grade II acute GVHD and extensive
chronic GVHD were observed before the development of
pulmonary Tb (Table 3). This patient had received pred-
nisolone for the treatment of acute GVHD for a period of
5 weeks beginning on day 45. Nine months after the
alloSCT, he was diagnosed with chronic extensive GVHD,
the symptoms of which were controlled with readministra-
tion of cyclosporin A. His Tb-related symptoms appeared
6 months after the diagnosis of chronic GVHD and
15 months after the alloSCT.
Of the 351 patients, 77 received INH chemoprophylaxis
for 6 months. None of these patients developed posttrans-
plantation Tb; 5 of the remaining 274 cases developed Tb
(4 pulmonary and 1 renal) 10 to 47 months (median,
13 months) after allografting (Table 3). All 3 patients from
center M were given the same antituberculous treatment
consisting of INH (300 mg/day) and rifampin (600 mg/day)
for 9 months and ethambutol hydrochloride (15 mg/kg per
day) and pyrazinamide (2 g/day) for 2 months. Patient 5
(center A) had similar antituberculous treatment but
received ethambutol and pyrazinamide for 3 months instead
of 2 months. Patient 4 (center A) received INH (300 mg/day)
and rifampin (600 mg/day) for 12 months, ethambutol
(15 mg/kg per day) for 4 months, and pyrazinamide
(2 g/day) for 2 months. In all cases, antituberculous therapy
resulted in complete eradication of the infection.
In 77 patients who received INH prophylactically, no
drug-related hepatotoxicity (defined as AST more than
5 times normal and development of hepatitis symptoms)
was observed. However, intervening hepatic GVHD
involvement in 9 patients and VOD in 4 patients necessi-
tated interruption of INH administration during the
search for the cause of hepatotoxicity. After evaluation and
treatment of liver function deterioration, INH prophy-
laxis was reestablished in 4 of the 13 patients; the other
9 patients (4 with VOD and 5 with acute GVHD) died of
transplant-related disorders.
DISCUSSION
In general, alloSCT recipients have impaired T-cell–
mediated cellular immunity as a consequence of the primary
Table 2. Posttransplantation Tuberculosis in Allogeneic Stem Cell Transplant Recipients by Pretransplantation Tuberculin Test and Isoniazid Prophylaxis*
Pretransplantation PPD Reaction, mm Isoniazid Prophylaxis
BMT Center <10 11-15 >15 Not Given Given
Ankara Ibni-Sina Hospital (n = 185)
Total ND ND ND 185 0
Developed posttransplantation tuberculosis — — — 2 —
Cerrahpasa School of Medicine (n = 50) ND ND ND 50 —
Marmara School of Medicine (n = 42)
Total 30 9 3 39 3
Developed posttransplantation tuberculosis 3 0 0 3 0
Istanbul School of Medicine (n = 74) 50 20 4 0 74
All centers (n = 351)
Total 80 29 7 274 77
Developed posttransplantation tuberculosis 3 0 0 5† 0†
*Data are n. PPD indicates puriﬁed protein derivative; ND, not done.
†P = .59 by Fisher exact test.
Table 3. Clinical Characteristics of Allogeneic Stem Cell Transplant Recipients Who Developed Posttransplantation Tuberculosis*
Pretransplantation Time of
BMT Primary Allograft PPD Reaction, Diagnosis, Infection aGVHD
Patient Unit Age, y Sex Diagnosis Source mm mo Site Grade cGVHD
1 M 21 M CML BM 6 >11 Pulmonary I —
2 M 16 F CML BM 4 >10 Renal I —
3 M 24 M AML BM 9 >47 Pulmonary I —
4† A 42 M AML PBSCs ND >12 Pulmonary 0 —
5† A 34 M CML PBSCs ND >15 Pulmonary II Extensive
*BMT indicates bone marrow transplantation; PPD, puriﬁed protein derivative; aGVHD, acute graft-versus-host disease; cGVHD; chronic graft-versus-
host disease; CML, chronic myeloid leukemia; BM, bone marrow; AML, acute myeloblastic leukemia; PBSCs, peripheral blood stem cells; ND; not done.
†Previously reported by Arslan et al. [8].
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disease itself or as adverse effects of the treatment, and they
usually require at least 12 months to recover that immunity
[14,15]. Therefore, a higher frequency of Tb infections
would be anticipated.
This retrospective survey shows that in adult alloSCT
recipients in Turkey, the risk of developing Tb after alloSCT
is not negligible. The observed posttransplantion Tb fre-
quency in our group (5 of 351 patients) was far greater than
the incidence of Tb in the general population of Turkey
(35.4 per 100,000) (Table 4) [9]. However, Tb infections in
alloSCT recipients occur less frequently than in solid organ
transplant recipients. This disparity may, at least in part, be due
to the long duration of immunosuppression in recipients of
solid organ transplants and the long-term persistence of trans-
ferred PPD-reactive T cells from the stem cell donor [4,6,7].
BCG is a compulsory vaccine for infants in Turkey; as
shown by Rouleau et al. [4], vaccination with BCG could pro-
vide anti-PPD reactive T-cell clones of donor origin in
alloSCT recipients. Therefore, the evaluation of donor tuber-
culin skin test reactivity before allografting may be valuable.
Despite previous vaccination, 80 of the 116 recipients
had a tuberculin reaction <10 mm (ie, PPD-negative) before
transplantation. On the other hand, in BMT unit M,
3 recipients who developed posttransplantation Tb (patients
3, 4, and 5) did not receive any prophylaxis because their
PPD results were <10 mm (Table 3). These 2 observations
raise the question as to whether PPD reactions should be
routinely tested in this group of patients and whether only
PPD-positive (>15 mm) candidates should receive INH.
In our study, none of the 77 patients under INH pro-
phylaxis developed Tb after alloSCT, and none experienced
deleterious INH-induced hepatotoxicity. INH chemopro-
phylaxis markedly reduces the risk of developing active Tb,
especially for recently infected individuals. Fatal INH-
related toxicity has been observed much less frequently than
had once been suggested [21]. Adherence to World Health
Organization guidelines for administration and monitoring
of INH prophylaxis has helped reduce its adverse effects
[21]. Furthermore, a recent study on renal transplant recipi-
ents showed that the risk of developing serious hepatotoxic-
ity after administration of INH was low and similar to that
of the normal individual [22]. No comparable INH toxicity
data for alloSCT recipients has been published.
According to our observations, Tb seems to be among
the late infections following alloSCT, and therefore the tim-
ing of INH chemoprophylaxis is also debatable. AlloSCT
recipients might start receiving INH prophylaxis 3 to
6 months after allografting, when interference from other
drug toxicities, GVHD, or VOD is usually much less than
during the ﬁrst 100 days.
All our patients with Tb, like the patients in the series
mentioned in Table 4, recovered successfully with antituber-
culous treatment. Therefore, treating the documented
infection at the time of diagnosis could also be an alternative
to chemoprophylaxis. Nevertheless, only randomized trials
can determine whether prophylaxis or treatment at diagno-
sis is a more efﬁcient approach for posttransplantation Tb.
There was no statistically significant difference in the
posttransplantation Tb frequency between the groups who
did (0 of 77) or did not (5 of 274) receive INH prophylaxis
(P = .59). However, the frequency of Tb among alloSCT
recipients in Turkey (5 of 351) was found to be far above that
in the general population (35.4 per 100,000). These data sug-
gest that the merits of INH prophylaxis among alloSCT
recipients should be addressed in a larger, randomized, con-
trolled clinical trial. Especially in countries where Tb is
prevalent, there should be meticulous pretransplantation
testing and posttransplantation follow-up for Tb. Also,
because INH was apparently well tolerated, we recommend
that the use of INH chemoprophylaxis should be considered.
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